Nottingham, United Kingdom

Bruce William Leslie

This inventor holds 3 USPTO granted patents. Top assignee: Knoll Aktiengesellschaft. Active years: 1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bruce William Leslie. Retrieved from https://idiyas.com/inventor/bruce-william-leslie

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 2.4

ph-index = 2

Forward Citations = 33(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Bruce William Leslie: Innovator in Pharmaceutical Chemistry

Introduction

Bruce William Leslie is a notable inventor based in Nottingham, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on various compounds. With a total of 3 patents to his name, Leslie has established himself as a key figure in his industry.

Latest Patents

Leslie's latest patents include groundbreaking research on naphthyridinone derivatives and condensed 4-aminopyridines with antirheumatic activity. These inventions showcase his commitment to developing new therapeutic options for patients suffering from various ailments.

Career Highlights

Leslie is currently employed at Knoll Aktiengesellschaft, a company known for its dedication to advancing healthcare through innovative solutions. His work at this organization has allowed him to further his research and contribute to the development of new medications.

Collaborations

Throughout his career, Leslie has collaborated with esteemed colleagues such as Bernard John Armitage and Thomas Kerr Miller. These partnerships have enriched his research and expanded the impact of his inventions.

Conclusion

In summary, Bruce William Leslie is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in the field. His contributions continue to influence the development of new treatments and improve patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…